Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of mRNA-3210 in phenylketonuria
2023-506963-32-00Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3210 in phenylketonuria (PKU), sponsored by Moderna Inc. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Jul 2024; status: completed.
02
Drugs
mRNA-3210
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2023-506963-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506963-32-00.